# Summary of minutes of EUCAST Steering Committee Meeting

**Dusseldorf, Germany 8-9 November 2015**

## Attending

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Derek F.J. Brown</td>
<td>Scientific Secretary</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Dr Rafael Cantón</td>
<td>Chairperson</td>
<td>Spain</td>
</tr>
<tr>
<td>Prof Gerard Lina</td>
<td>CA-SFM</td>
<td>France</td>
</tr>
<tr>
<td>Dr Christian Giske</td>
<td>SRGA</td>
<td>Sweden</td>
</tr>
<tr>
<td>Prof Gunnar Kahlmeter</td>
<td>Clinical Data Co-ordinator</td>
<td>Sweden</td>
</tr>
<tr>
<td>Dr P. Christoffer Lindemann</td>
<td>NWGA</td>
<td>Norway</td>
</tr>
<tr>
<td>Dr Mandly Wootton</td>
<td>BSAC</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Prof Johan W. Mouton</td>
<td>CRG</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>Prof Sören Gatermann</td>
<td>German NAC</td>
<td>Germany</td>
</tr>
<tr>
<td>Dr Iztok Štrumbelj</td>
<td>EUCAST General Committee</td>
<td>Slovenia</td>
</tr>
<tr>
<td>Prof Alasdair P. MacGowan</td>
<td>BSAC</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Prof Jan Verhagen</td>
<td>EUCAST General Committee</td>
<td>Belgium</td>
</tr>
<tr>
<td>EMA representative</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dr Radu Botgros</td>
<td></td>
<td>UK</td>
</tr>
<tr>
<td>Visiting members</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prof George Drusano</td>
<td>USCAST</td>
<td>USA</td>
</tr>
</tbody>
</table>

## Apologies

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prof George Drusano</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Chairmen’s welcome

RC welcomed GD as visiting member from the General Committee, and MW attending as the BSAC representative in place of AM.

## Minutes of meeting of 7-8 September 2015

Accepted as a correct record.

## Matters arising from minutes of 7-8 September 2015 (items not covered by agenda)

None.

## New agents

Draft breakpoints for ceftazidime-avibactam were discussed.

Ceftolozane-tazobactam received a positive opinion from EMA and this has been ratified by the European Commission.

## EUCAST rationale documents

The ceftobiprole document will be released.

Telavancin, dalbavancin, oritavancin and tedizolid documents are being drafted.

Ampicillin, amoxicillin-clavulanic acid and trimethoprim-sulfamethoxazole documents are to be updated to the latest format and will then be released.

## Subcommittees

**Antifungal susceptibility testing (AFST):** Breakpoints for isavuconazole have been completed. Jesus Guinea Ortega has taken over as Scientific Secretary of AFST.

Whole genome sequencing (WGS): The first draft of a report is being prepared.

VetCAST: Data are being collected, structures established and standardisation of methodology is being discussed.

ECOFFs: Proposed subcommittee members have been invited to participate.

Antimycobacterial susceptibility testing: It was agreed to set up a subcommittee.

## Breakpoint issues

An updated draft of breakpoint tables version 6.0 was reviewed.

The revised intermediate category definition has been released for consultation.
Colistin breakpoints are under review.

A proposal for carbapenem breakpoint changes is to be prepared.

Revised intrinsic resistance and unusual resistance tables have been released for consultation.

Changes to macrolide breakpoint categorisation of the wild type H. influenzae were discussed.

A guidance document giving the background to the “IE” breakpoint designation for daptomycin and enterococci is being prepared.

Discussion of changes to tigecycline breakpoints for Enterbacteriaceae is in progress.

Proposed nitrooxoline breakpoints have been released for consultation.

Cefoxitin disk diffusion breakpoints for different species of coagulase-negative staphylococci are being examined.

β-Lactam breakpoints are being examined in relation to oral administration.

Vancomycin surrogate testing for susceptibility to lipoglycopeptides was approved.

The absence of clinical data relating benzylpenicillin MIC to outcome for N. meningitidis was noted.

It was agreed that “agent of last resort” is not a good argument for higher breakpoints than indicated by PK-PD data.

The comment in breakpoint tables on ESBL and carbapenemase detection with be changed to “ESBL and carbapenemase detection and characterisation is recommended for public health and infection control purposes”.

A review of aminoglycoside breakpoints has been started.

**8 Organisms without EUCAST breakpoints**

In vitro data required for setting breakpoints for Aerococcus spp. and Kingella kingae are progressing.

A guidance note on how laboratories should deal with isolates of organisms without breakpoints is being drafted.

**9 EUCAST methods**

The EUCAST Development Laboratory is working on a range of projects related to EUCAST breakpoints and methods.

The first section of a WHO video on the disk diffusion method has been prepared. A guidance document on Legionella pneumophila susceptibility testing is being prepared.

**10 Implementation of EUCAST breakpoints** EUCAST breakpoints and methods are being adopted in some South American countries and South Africa.

**11 EUCAST websites**

A section with all open consultations and responses is being prepared.

A graph of numbers of website visitors and maps on the establishment of NACs, use of EUCAST breakpoints and adoption of the disk diffusion method have been added to the website.

**12 Publications and presentations** A leading article, “Antimicrobial susceptibility testing breakpoints and methods from BSAC to EUCAST”, has been published in JAC.

**13 NACs** A Canadian NAC is being formed.
EUCAST documents
A revised version of SOP 3.0, Revision of breakpoints, has been released.

Changes to SOP 4.1, Committees and subcommittees, were agreed. The guidelines for the detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance are being updated.

ESCMID
A draft program was agreed for the postgraduate educational course on antimicrobial susceptibility testing and surveillance to be held in Bochum, Germany in September 2016.

The ESCMID Executive Committee has approved changes to the Steering Committee.

EMA
Revision of the EMA-EUCAST SOP is being discussed with companies.

ECDC
A new EUCAST contract has been signed.

CLSI
CLSI will be informed that the EUCAST Chair will change after the 2016 ECCMID meeting.

Any other business
The Scientific Secretary job description is being drafted.

Next meetings
8-9 February 2016, Madrid, Spain
12-13 April 2016, Amsterdam, The Netherlands
4-5 July 2016, Stockholm, Sweden
19-20 September 2016, Bochum, Germany (before PGEC)
21-22 November 2016, Windsor, London (to be confirmed)

Ratified summary of minutes of meeting 8-9 November 2015. Prepared by DB, RC, CG and GK